Abalos

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.

Press releases

15. October 2019
Abalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer
Abalos Therapeutics announced today a EUR 12 million Series A financing round establishing its operations and leadership.  The Company’s objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating a strong anti-tumor immune response. The Series A round was co-led by Boehringer Ingelheim Venture Fund (BIVF) and Gruenderfonds Ruhr, with participation from NRW.BANK and High-Tech Gründe
 

Info & Contact

kostka@abalos-tx.com
Web:
www.abalos-tx.com

Address

Alfredstraße 81
45130 Essen
Germany

In portfolio

10. Jul 2019

HTGF Manager

 
Dr. Frank Hensel, Principal / Authorized signatory